This is Metabolon’s second project with NCI but first project as a member of the EDRN will be a collaboration with the University of Michigan to discover disease biomarkers for prostate cancer.
"Membership in the EDRN is a great privilege," said Dr. John Ryals, president and CEO of Metabolon.
"Metabolon will be able to collaborate with other members to discover and develop biomarkers for the early diagnosis of cancers."
Metabolon will share its technology and metabolomics expertise with Dr. Arul Chinnaiyan of the University of Michigan on the prostate cancer project.
"Metabolon is at the forefront in the emerging area of metabolomics, and we are extremely excited about embarking on this collaboration," said Dr. Chinnaiyan.
"If metabolomic biomarkers can be identified for prostate cancer, Metabolon’s technology platform may have applications in other cancers as well."